Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Angiogenesis-VEGF
3. Angiogenesis-VEGF-C/D
4. VEGF and VEGFR tyrosine kinase
5. Strategies to inhibition of VEGFR signaling
6. MuMAb VEGF
7. RhuMAb VEGF-Avastin
8. Blocking Ab differ from other agents
9. Anti-VEGF Ab prevents VEGF/VEGFR interaction
10. Potential effects of inhibiting VEGF
11. Anti-angiogenesis 'normalizes' tumour vasculature
12. Anti-VEGF Ab modifies tumour vasculature
13. VEGF inhibition can induce capillary regression
14. Ranbizumab
15. Pegaptabin
16. 'Metronomic' anti-angiogenic chemotherapy
17. Preclinical models
18. Potential effects of anti-VEGF therapy
19. Anti-VEGFR2 Mab
20. Treatment of human xenograph tumors with DC101
21. VEGFR-2 blockade
22. VEGFR-2 block leads to increase in tumor hypoxia
23. Anti-VEGFR-2 MAb and gemcitabine
24. VEGFR-2 Ab IMC-1121b
25. Structure and properties of VEGF trap
26. Angiogenesis inhibitors in clinical trials
27. Tumor lymphangiogenesis and metastasis
28. VEGF - C/D trap prevents VEGFR-3 signaling
29. VEGF - C/D trap prevents lymph vessels growth
30. Inhibition of tumor lymphangiogenesis
31. Blocking metastasis to lymph nodes
32. Model of lymphatic metastasis
33. Model of prevention of lymphatic metastasis
34. Proteolytic processing of VEGF-C/D
35. VEGF in hematogenous and lymphatic spread
36. Conclusions (1)
37. Conclusions (2)

Topics Covered

• Strategies to inhibit VEGFR signaling
• Potential effects of inhibiting VEGF
• Effects of anti-angiogenic therapy in preclinical models
• Treatment of Human Xenograft Tumors With DC101
• Combination Therapy with Anti-VEGFR-2 MAb and Gemcitabine
• Examples of angiogenesis inhibitors in clinical trials
• Inhibition of tumor lymphangiogenesis and lymph node metastasis with VEGFR-3-Fc

Links

Series:

• Signal Transduction via Protein Tyrosine Kinase Receptors

Categories:

• Biochemistry
• Cancer
• Pharmaceutical Sciences

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on May 31, 2018

Financial Disclosures

• Prof. Kari Alitalo has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.